247 related articles for article (PubMed ID: 37690071)
21. CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD.
Gispert JD; Monté GC; Falcon C; Tucholka A; Rojas S; Sánchez-Valle R; Antonell A; Lladó A; Rami L; Molinuevo JL
Neurobiol Aging; 2016 Feb; 38():47-55. PubMed ID: 26827642
[TBL] [Abstract][Full Text] [Related]
22. Cerebral amyloid-β load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's continuum.
Salvadó G; Milà-Alomà M; Shekari M; Minguillon C; Fauria K; Niñerola-Baizán A; Perissinotti A; Kollmorgen G; Buckley C; Farrar G; Zetterberg H; Blennow K; Suárez-Calvet M; Molinuevo JL; Gispert JD;
Alzheimers Dement; 2021 May; 17(5):788-800. PubMed ID: 33663013
[TBL] [Abstract][Full Text] [Related]
23. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
[TBL] [Abstract][Full Text] [Related]
25. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease.
Lantero-Rodriguez J; Salvadó G; Snellman A; Montoliu-Gaya L; Brum WS; Benedet AL; Mattsson-Carlgren N; Tideman P; Janelidze S; Palmqvist S; Stomrud E; Ashton NJ; Zetterberg H; Blennow K; Hansson O
Mol Neurodegener; 2024 Feb; 19(1):19. PubMed ID: 38365825
[TBL] [Abstract][Full Text] [Related]
26. Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.
Dark HE; An Y; Duggan MR; Joynes C; Davatzikos C; Erus G; Lewis A; Moghekar AR; Resnick SM; Walker KA
Alzheimers Res Ther; 2024 Apr; 16(1):94. PubMed ID: 38689358
[TBL] [Abstract][Full Text] [Related]
27. Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability.
Simrén J; Weninger H; Brum WS; Khalil S; Benedet AL; Blennow K; Zetterberg H; Ashton NJ
Alzheimers Dement; 2022 Oct; 18(10):1988-1992. PubMed ID: 36102852
[TBL] [Abstract][Full Text] [Related]
28. An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum.
Van Hulle C; Jonaitis EM; Betthauser TJ; Batrla R; Wild N; Kollmorgen G; Andreasson U; Okonkwo O; Bendlin BB; Asthana S; Carlsson CM; Johnson SC; Zetterberg H; Blennow K
Alzheimers Dement; 2021 Mar; 17(3):431-445. PubMed ID: 33336877
[TBL] [Abstract][Full Text] [Related]
29. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia.
Abu-Rumeileh S; Steinacker P; Polischi B; Mammana A; Bartoletti-Stella A; Oeckl P; Baiardi S; Zenesini C; Huss A; Cortelli P; Capellari S; Otto M; Parchi P
Alzheimers Res Ther; 2019 Dec; 12(1):2. PubMed ID: 31892365
[TBL] [Abstract][Full Text] [Related]
30. Glial activation and inflammation along the Alzheimer's disease continuum.
Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
[TBL] [Abstract][Full Text] [Related]
31. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease.
Palmqvist S; Insel PS; Stomrud E; Janelidze S; Zetterberg H; Brix B; Eichenlaub U; Dage JL; Chai X; Blennow K; Mattsson N; Hansson O
EMBO Mol Med; 2019 Dec; 11(12):e11170. PubMed ID: 31709776
[TBL] [Abstract][Full Text] [Related]
32. Combination of plasma amyloid beta
Verberk IMW; Thijssen E; Koelewijn J; Mauroo K; Vanbrabant J; de Wilde A; Zwan MD; Verfaillie SCJ; Ossenkoppele R; Barkhof F; van Berckel BNM; Scheltens P; van der Flier WM; Stoops E; Vanderstichele HM; Teunissen CE
Alzheimers Res Ther; 2020 Sep; 12(1):118. PubMed ID: 32988409
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease.
Yakoub Y; Ashton NJ; Strikwerda-Brown C; Montoliu-Gaya L; Karikari TK; Kac PR; Gonzalez-Ortiz F; Gallego-Rudolf J; Meyer PF; St-Onge F; Schöll M; Soucy JP; Breitner JCS; Zetterberg H; Blennow K; Poirier J; Villeneuve S;
Alzheimers Dement; 2023 Dec; 19(12):5620-5631. PubMed ID: 37294682
[TBL] [Abstract][Full Text] [Related]
34. Modeling the temporal evolution of plasma p-tau in relation to amyloid beta and tau PET.
Cogswell PM; Lundt ES; Therneau TM; Wiste HJ; Graff-Radford J; Algeciras-Schimnich A; Lowe VJ; Mielke MM; Schwarz CG; Senjem ML; Gunter JL; Knopman DS; Vemuri P; Petersen RC; Jack CR
Alzheimers Dement; 2024 Feb; 20(2):1225-1238. PubMed ID: 37963289
[TBL] [Abstract][Full Text] [Related]
35. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum.
Milà-Alomà M; Salvadó G; Gispert JD; Vilor-Tejedor N; Grau-Rivera O; Sala-Vila A; Sánchez-Benavides G; Arenaza-Urquijo EM; Crous-Bou M; González-de-Echávarri JM; Minguillon C; Fauria K; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Suárez-Calvet M; Molinuevo JL;
Alzheimers Dement; 2020 Oct; 16(10):1358-1371. PubMed ID: 32573951
[TBL] [Abstract][Full Text] [Related]
36. Association of glial and neuronal degeneration markers with Alzheimer's disease cerebrospinal fluid profile and cognitive functions.
Teitsdottir UD; Jonsdottir MK; Lund SH; Darreh-Shori T; Snaedal J; Petersen PH
Alzheimers Res Ther; 2020 Aug; 12(1):92. PubMed ID: 32753068
[TBL] [Abstract][Full Text] [Related]
37. Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study.
Salvadó G; Larsson V; Cody KA; Cullen NC; Jonaitis EM; Stomrud E; Kollmorgen G; Wild N; Palmqvist S; Janelidze S; Mattsson-Carlgren N; Zetterberg H; Blennow K; Johnson SC; Ossenkoppele R; Hansson O
Alzheimers Dement; 2023 Jul; 19(7):2943-2955. PubMed ID: 36648169
[TBL] [Abstract][Full Text] [Related]
38. Comparative Analysis of Different Definitions of Amyloid-β Positivity to Detect Early Downstream Pathophysiological Alterations in Preclinical Alzheimer.
Milà-Alomà M; Salvadó G; Shekari M; Grau-Rivera O; Sala-Vila A; Sánchez-Benavides G; Arenaza-Urquijo EM; González-de-Echávarri JM; Simon M; Kollmorgen G; Zetterberg H; Blennow K; Gispert JD; Suárez-Calvet M; Molinuevo JL
J Prev Alzheimers Dis; 2021; 8(1):68-77. PubMed ID: 33336227
[TBL] [Abstract][Full Text] [Related]
39. Relationships between PET and blood plasma biomarkers in corticobasal syndrome.
Singh NA; Alnobani A; Graff-Radford J; Machulda MM; Mielke MM; Schwarz CG; Senjem ML; Jack CR; Lowe VJ; Kanekiyo T; Josephs KA; Whitwell JL
Alzheimers Dement; 2024 Jun; ():. PubMed ID: 38885334
[TBL] [Abstract][Full Text] [Related]
40. Measures of cortical microstructure are linked to amyloid pathology in Alzheimer's disease.
Spotorno N; Strandberg O; Vis G; Stomrud E; Nilsson M; Hansson O
Brain; 2023 Apr; 146(4):1602-1614. PubMed ID: 36130332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
